8-K
filed November 16, 2023, 6:59 PM ET
ticker ANGO
CIK 0001275187
other
confidence high
sentiment neutral
materiality 0.30
AngioDynamics shareholders approve amended equity plan and elect directors at annual meeting
ANGIODYNAMICS INC
- All four board nominees elected with votes ranging from 23.6M to 25.9M for; avg 24.7M for, 1.9M withheld.
- Amended 2020 Equity Incentive Plan approved with 24.1M for and 2.5M against (excl. 5.8M broker non-votes).
- Advisory say-on-pay approved with 24.4M for, 2.2M against; annual frequency vote also passed.
- Ratification of Deloitte & Touche as auditor for FY ending May 31, 2024: 32.4M for, 11K against.
- Company will hold advisory say-on-pay votes annually until next required frequency vote.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANGIODYNAMICS INC shareholders approved Election of Class II directors at the 2023-11-14 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-11-14
Exact text from the filing
1. The nominees for election to the Board of Directors of AngioDynamics were elected, each as a Class II director to serve until the 2026 Annual Meeting of Shareholders of AngioDynamics and until their respective successors are duly elected and qualified, based upon the following votes: Nominee Votes For Withheld Broker Non-Votes Eileen O. Auen 23,553,074 3,039,968 5,784,837 James C. Clemmer 25,883,397 709,645 5,784,837 Howard W. Donnelly 24,605,006 1,988,036 5,784,837 Jan Stern Reed 24,900,465 1,692,577 5,784,837
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANGIODYNAMICS INC shareholders approved Advisory approval of executive compensation (Say On Pay) at the 2023-11-14 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-11-14
Exact text from the filing
3. The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers (“Say On Pay”) was approved based upon the following votes: Votes for approval 24,393,365 Votes against 2,193,446 Abstentions 6,231 Broker non-votes 5,784,837
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANGIODYNAMICS INC shareholders approved Approve amendments to the AngioDynamics, Inc. 2020 Equity Incentive Plan at the 2023-11-14 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-11-14
Exact text from the filing
4. The proposal to approve amendments to the AngioDynamics, Inc. 2020 Equity Incentive Plan was approved based upon the following votes: Votes for approval 24,111,357 Votes against 2,461,478 Abstentions 20,207 Broker non-votes 5,784,837
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANGIODYNAMICS INC shareholders approved Advisory vote on frequency of Say On Pay vote at the 2023-11-14 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-11-14
Exact text from the filing
5. The proposal to approve, on an advisory basis the frequency of the Say On Pay vote was approved to take place annually based upon the following votes: Votes for 1 year 24,882,516 Votes for 2 years 5,024 Votes for 3 years 1,696,442 Abstentions 9,060 Broker non-votes 5,784,837
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ANGIODYNAMICS INC shareholders approved Ratify appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-11-14 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-11-14
Exact text from the filing
2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2024 was approved based upon the following votes: Votes for approval 32,364,352 Votes against 11,237 Abstentions 2,290 There were no broker non-votes for this item.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.